Vertex Pharmaceutic (VRTX)

$421.39 -1.24 (-0.29%)
Market Cap 108.36B
Revenue (ttm) 11.02B
Net Income (ttm) -535.60M
EPS (ttm) N/A
PE Ratio 28.19
Forward PE 26.84
Profit Margin -4.86%
Debt to Equity Ratio 0.00
Volume 1,004,900
Avg Vol 1,530,454
Day's Range N/A - N/A
Shares Out 256.39M
Stochastic %K 58%
Beta 0.43
Analysts Strong Sell
Price Target $490.60

Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
butcalloption
butcalloption Oct. 24 at 2:13 AM
$VRTX
0 · Reply
JohnCosta3086
JohnCosta3086 Oct. 23 at 9:24 PM
Tape is smoking — catalysts near, volume rising! Portfolio: $MSFT $MRNA $HON $VRTX $BF.B Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. MSFT shows relative strength; MRNA is base-building; HON is a stealth accumulator; VRTX offers sector exposure; BF.B provides stability. Execution: Plan: small starter position, scale with a confirmed trend; respect risk. #MarketPulse #Technical Source: https://stocktwits.com/MarkSavage8573/message/632828492
0 · Reply
KennethVargas1265
KennethVargas1265 Oct. 23 at 7:43 PM
High-conviction cluster — risk-defined entries only! Portfolio: $WYNN $CHRW $BAC $GILD $VRTX Why this cluster: Quiet buy-side interest + improving breadth — watch for volume confirmation. WYNN shows relative strength; CHRW is base-building; BAC is a stealth accumulator; GILD offers sector exposure; VRTX provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #StocksToWatch #Momentum Source:https://stocktwits.com/GaryBrown7417/message/632828520
0 · Reply
VincentWarren7016
VincentWarren7016 Oct. 23 at 4:18 PM
Breaking: momentum cluster forming — watch closely! Portfolio: $VRTX $HLT $BLK $DIS $BHP Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. VRTX shows relative strength; HLT is base-building; BLK is a stealth accumulator; DIS offers sector exposure; BHP provides stability. Execution: Watch: monitor news flow and intraday volume for confirmation before heavy sizing. #MarketPulse #Technical Source: https://stocktwits.com/AngelaBeck8757/message/632828768
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 23 at 2:32 PM
🏛️ 🚀 $VRTX up ⬆️13.79% since our entry $379.72 on Sep 23, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
JCLuckman
JCLuckman Oct. 23 at 12:51 PM
$VRTX Ol Rich Pappy! 💪 Sleep Easy!! $500 by 🎄
0 · Reply
Annbwilliam
Annbwilliam Oct. 23 at 9:44 AM
Everyone wants the next $LLY or $VRTX — $VKTX is walking that path before most notice.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 12:09 AM
Enter: $VRTX NOV 14 2025 $430 CALLS Buy in Price: $12.35 - $17.90 Take Profit: $25.07 Stop Bleeding: $10.87 ROI Potential: 103% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
akinyo
akinyo Oct. 22 at 3:49 PM
$VRTX solid!
0 · Reply
Prester_John
Prester_John Oct. 22 at 3:36 PM
$VRTX Andrew Fein has given his Buy rating due to a combination of factors that highlight the promising potential of Vertex Pharmaceuticals’ kidney franchise. The company’s innovative approach with povetacicept, which employs a dual BAFF/APRIL blockade, is seen as offering more profound and lasting disease control compared to single-pathway treatments. This is supported by early data indicating significant proteinuria reduction and stabilization of eGFR, suggesting a multi-billion-dollar opportunity with a clear path to becoming a first-in-class treatment. Fein also notes the strategic significance of Vertex’s expansion into primary membranous nephropathy (PMN), a condition with no approved therapies, positioning povetacicept as a potential first-in-class option. https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-promising-kidney-franchise-andrew-feins-buy-rating-on-innovative-povetacicept-and-strategic-expansion-ratings
0 · Reply
Latest News on VRTX
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Oct 23, 2025, 9:00 AM EDT - 2 days ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Oct 17, 2025, 9:04 AM EDT - 8 days ago

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Oct 6, 2025, 4:00 PM EDT - 18 days ago

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

Oct 2, 2025, 1:31 PM EDT - 22 days ago

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

IJR NOW

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Sep 25, 2025, 1:39 PM EDT - 4 weeks ago

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Vertex Announces Key Advancements Across Kidney Portfolio

Sep 25, 2025, 7:45 AM EDT - 4 weeks ago

Vertex Announces Key Advancements Across Kidney Portfolio

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

Sep 23, 2025, 9:00 AM EDT - 4 weeks ago

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 7:53 AM EDT - 4 weeks ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Sep 18, 2025, 8:30 AM EDT - 5 weeks ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality

Sep 13, 2025, 8:19 AM EDT - 6 weeks ago

Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Sep 11, 2025, 9:05 AM EDT - 6 weeks ago

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (VRTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 2:01 PM EDT - 6 weeks ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 6 weeks ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VEEV VST

Vertex Pharmaceuticals Incorporated (VRTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 3, 2025, 3:57 PM EDT - 7 weeks ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

Sep 2, 2025, 9:00 AM EDT - 7 weeks ago

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

Vertex to Participate in Upcoming September Investor Conferences

Aug 20, 2025, 4:00 PM EDT - 2 months ago

Vertex to Participate in Upcoming September Investor Conferences

Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More

Aug 18, 2025, 9:01 AM EDT - 2 months ago

Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More

ADBE

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

Aug 12, 2025, 2:34 PM EDT - 2 months ago

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)

Aug 11, 2025, 4:47 PM EDT - 2 months ago

Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)

Weakness In Vertex Stock Seen As Buying Opportunity

Aug 5, 2025, 2:05 PM EDT - 2 months ago

Weakness In Vertex Stock Seen As Buying Opportunity

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

Aug 5, 2025, 1:58 PM EDT - 2 months ago

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Aug 5, 2025, 10:25 AM EDT - 2 months ago

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Aug 5, 2025, 8:09 AM EDT - 2 months ago

Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

ICHR INSP

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:13 PM EDT - 2 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript

Vertex tops estimates on cystic fibrosis treatment strength, new products

Aug 4, 2025, 5:40 PM EDT - 2 months ago

Vertex tops estimates on cystic fibrosis treatment strength, new products

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings

Aug 4, 2025, 5:13 PM EDT - 2 months ago

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings

Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates

Aug 4, 2025, 4:59 PM EDT - 2 months ago

Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates

Vertex to stop developing new painkiller as solo treatment after mid-stage study setback

Aug 4, 2025, 4:24 PM EDT - 2 months ago

Vertex to stop developing new painkiller as solo treatment after mid-stage study setback

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

Aug 4, 2025, 4:01 PM EDT - 2 months ago

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

Vertex Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:01 PM EDT - 2 months ago

Vertex Reports Second Quarter 2025 Financial Results

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Aug 4, 2025, 1:48 PM EDT - 2 months ago

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

How Will VRTX Stock React To Its Upcoming Earnings?

Aug 2, 2025, 12:20 AM EDT - 3 months ago

How Will VRTX Stock React To Its Upcoming Earnings?

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

Jul 31, 2025, 9:52 AM EDT - 3 months ago

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

BSX CAH DXCM EW ISRG LLY PODD

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Jul 14, 2025, 7:01 PM EDT - 3 months ago

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

Jul 14, 2025, 8:30 AM EDT - 3 months ago

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch

Jul 9, 2025, 3:09 PM EDT - 3 months ago

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

Jul 8, 2025, 4:00 PM EDT - 3 months ago

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

Jul 8, 2025, 10:41 AM EDT - 3 months ago

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

BMY GILD JNJ NVO PFE

Vertex's next-generation cystic fibrosis drug gets EU approval

Jul 1, 2025, 7:46 AM EDT - 4 months ago

Vertex's next-generation cystic fibrosis drug gets EU approval

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Jul 1, 2025, 7:34 AM EDT - 4 months ago

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

Jun 23, 2025, 4:00 AM EDT - 4 months ago

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript

Jun 22, 2025, 8:32 PM EDT - 4 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

Jun 20, 2025, 7:15 PM EDT - 4 months ago

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 10, 2025, 6:07 PM EDT - 4 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

Jun 6, 2025, 12:00 PM EDT - 5 months ago

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

May 30, 2025, 11:01 AM EDT - 5 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?

May 23, 2025, 9:46 AM EDT - 5 months ago

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?

Vertex to Participate in Upcoming Investor Conferences

May 15, 2025, 4:05 PM EDT - 5 months ago

Vertex to Participate in Upcoming Investor Conferences

butcalloption
butcalloption Oct. 24 at 2:13 AM
$VRTX
0 · Reply
JohnCosta3086
JohnCosta3086 Oct. 23 at 9:24 PM
Tape is smoking — catalysts near, volume rising! Portfolio: $MSFT $MRNA $HON $VRTX $BF.B Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. MSFT shows relative strength; MRNA is base-building; HON is a stealth accumulator; VRTX offers sector exposure; BF.B provides stability. Execution: Plan: small starter position, scale with a confirmed trend; respect risk. #MarketPulse #Technical Source: https://stocktwits.com/MarkSavage8573/message/632828492
0 · Reply
KennethVargas1265
KennethVargas1265 Oct. 23 at 7:43 PM
High-conviction cluster — risk-defined entries only! Portfolio: $WYNN $CHRW $BAC $GILD $VRTX Why this cluster: Quiet buy-side interest + improving breadth — watch for volume confirmation. WYNN shows relative strength; CHRW is base-building; BAC is a stealth accumulator; GILD offers sector exposure; VRTX provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #StocksToWatch #Momentum Source:https://stocktwits.com/GaryBrown7417/message/632828520
0 · Reply
VincentWarren7016
VincentWarren7016 Oct. 23 at 4:18 PM
Breaking: momentum cluster forming — watch closely! Portfolio: $VRTX $HLT $BLK $DIS $BHP Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. VRTX shows relative strength; HLT is base-building; BLK is a stealth accumulator; DIS offers sector exposure; BHP provides stability. Execution: Watch: monitor news flow and intraday volume for confirmation before heavy sizing. #MarketPulse #Technical Source: https://stocktwits.com/AngelaBeck8757/message/632828768
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 23 at 2:32 PM
🏛️ 🚀 $VRTX up ⬆️13.79% since our entry $379.72 on Sep 23, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
JCLuckman
JCLuckman Oct. 23 at 12:51 PM
$VRTX Ol Rich Pappy! 💪 Sleep Easy!! $500 by 🎄
0 · Reply
Annbwilliam
Annbwilliam Oct. 23 at 9:44 AM
Everyone wants the next $LLY or $VRTX — $VKTX is walking that path before most notice.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 12:09 AM
Enter: $VRTX NOV 14 2025 $430 CALLS Buy in Price: $12.35 - $17.90 Take Profit: $25.07 Stop Bleeding: $10.87 ROI Potential: 103% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
akinyo
akinyo Oct. 22 at 3:49 PM
$VRTX solid!
0 · Reply
Prester_John
Prester_John Oct. 22 at 3:36 PM
$VRTX Andrew Fein has given his Buy rating due to a combination of factors that highlight the promising potential of Vertex Pharmaceuticals’ kidney franchise. The company’s innovative approach with povetacicept, which employs a dual BAFF/APRIL blockade, is seen as offering more profound and lasting disease control compared to single-pathway treatments. This is supported by early data indicating significant proteinuria reduction and stabilization of eGFR, suggesting a multi-billion-dollar opportunity with a clear path to becoming a first-in-class treatment. Fein also notes the strategic significance of Vertex’s expansion into primary membranous nephropathy (PMN), a condition with no approved therapies, positioning povetacicept as a potential first-in-class option. https://www.tipranks.com/news/ratings/vertex-pharmaceuticals-promising-kidney-franchise-andrew-feins-buy-rating-on-innovative-povetacicept-and-strategic-expansion-ratings
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Oct. 22 at 2:58 PM
$VRTX RSI: 64.73, MACD: 6.9124 Vol: 12.32, MA20: 407.76, MA50: 397.88 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
cuttail07
cuttail07 Oct. 22 at 2:56 PM
$VRTX ARCT with disappointing results, further solidifying Vertex’s dominance in CF.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 11:21 PM
Enter: $VRTX NOV 14 2025 $430 CALLS Buy in Price: $12.35 - $16.90 Take Profit: $15.68 Stop Bleeding: $10.87 ROI Potential: 27% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 21 at 11:14 PM
$VRTX Share Price: $426.25 Contract Selected: Nov 14, 2025 $430 Calls Buy Zone: $10.62 – $13.12 Target Zone: $19.94 – $24.37 Potential Upside: 77% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 21 at 8:04 PM
$VRTX $450 coming to a theatre near you...
0 · Reply
svertical1
svertical1 Oct. 21 at 5:45 PM
$VRTX Bodes repeating…..$460 for gap fill
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 21 at 3:24 PM
$VRTX looking good 0:)
0 · Reply
svertical1
svertical1 Oct. 21 at 3:09 PM
$VRTX Once again WS Analysts are missing the significance of this and are way under estimating the value of Vertex’s pipeline.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 11:50 PM
Enter: $VRTX NOV 14 2025 $420 CALLS Buy in Price: $17.42 - $19.50 Take Profit: $28.74 Stop Bleeding: $15.33 ROI Potential: 65% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
JoeB07
JoeB07 Oct. 20 at 9:14 PM
$INSM $LQDA $UTHR $VRTX granted this is a sample size. Key data- these pulmonologists each wrote an average of 9x prescriptions which covered 10% of their patients. So in this sample 10% of eligible NCFB patients got a prescription in the first month post launch? That's pretty d8mn impressive. Imagine how many more they will reach in Q4. Excited to see Q4 numbers at JPM in January....
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 20 at 4:10 PM
$VRTX Take us higher... nice breaking point here.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 19 at 9:51 PM
Enter: $VRTX NOV 14 2025 $420 CALLS Buy in Price: $16.20 - $19.20 Take Profit: $23.33 Stop Bleeding: $14.26 ROI Potential: 44% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply